Gilead to Present New Data on Treatment Response and Long-Term Management of Rare Liver Diseases at The Liver Meeting® 2026

Gilead will present 21 abstracts at The Liver Meeting 2026 (AASLD, November 5-9, Denver), spanning late-breaking Phase 3 IDEAL study data on Livdelzi in PBC and long-term/real-world evidence for Hepcludex in chronic hepatitis delta. The IDEAL data examine composite ALP normalization in a previously understudied PBC population with lower ALP elevation, plus up to five years of seladelpar safety and efficacy and fatigue outcomes.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.